NEW YORK, July 29, 2015 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTC:AXIM) CEO George E. Anastassov, MD, DDS, MBA, proudly shared the Company's cannabinoid delivery methods – including the world's first patented cannabinoid release chewing gum - at the My Compassion Chicago Cannabis Conference. The three-day conference took place at Chicago's Navy Pier and focused on medical cannabis and hemp education with patients, industry professionals and the public.
"We sincerely appreciate My Compassion hosting the 2nd Annual Chicago Cannabis Conference and including AXIM Biotech as a presenter on cannabinoid delivery methods," states Dr. George E. Anastassov. "We were able to educate healthcare and legal professionals, patients and the news media. It was an invaluable experience and AXIM looks forward to supporting My Compassion in the future."
Complete use of the industrial hemp plant is at the core of the Company's business plan, which aims to use the natural plant to benefit human health, while providing clean alternative energy and delivering many other innovative applications. By focusing efforts on unique proprietary delivery mechanisms for the introduction of cannabinoids (e.g. CBD, CBG, CBN), AXIM Biotechnologies has charted a course and is actively developing solutions for conditions for which there currently are no effective treatments including: Parkinson's disease, Alzheimer's disease / dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn's disease.
Dr. Anastassov continues, "AXIM is committed to developing hemp-based solutions for conditions with no known cure. Research of these conditions including epilepsy, auto-immune disorders, and post-traumatic stress disorder / PTSD, were discussed at the Chicago Cannabis Conference. Those that attended gained access to valuable resources that are available today as well as knowledge of what is to come in the near future."
AXIM Biotech also creates strategic partnerships and acquisitions, allowing ongoing research and development in the areas of functional foods, nutraceuticals, pharmaceuticals, cosmetics, and clean energy – all derived from the industrial hemp plant. For more information, visit AXIM Biotech's website.
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@CMWmedia.com or call 858-380-5478.
AXIM Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.
CONTACT: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
Source:AXIM Biotechnologies, Inc